Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

Researchers used cryo-EM, glycoproteomics, and modeling to generate the atomic structure of a fully glycosylated and membrane ...

The study revealed that people with PVS symptoms had lower levels of two types of white blood cells, while people with PVS who never had COVID also had lesser antibodies against the SARS-CoV-2 spike ...

People with PVS who had never had COVID also had lower levels of antibodies against the SARS-CoV-2 spike protein, likely because they tended to have fewer vaccine doses, according to the release.

The spike protein of the new coronavirus infected human cells that had high levels of the ACE2 receptor in test tubes, as well as in small models of human airways and intestines. The researchers ...

According to researchers, HKU5-CoV-2 could pose significant risks if it adapts to human hosts, especially given its spike protein mutations that may help it evade immune responses. The detection ...

But their Feb. 18 preprint research, not yet peer-reviewed, also found alarming levels of spike protein – the primary mechanism for mRNA COVID vaccines – in the blood of never-infected participants as ...

The paper has not been peer-reviewed. Post-vaccination syndrome patients had lower levels of antibodies against the SARS-CoV-2 spike protein versus healthy controls, likely because they stopped ...